Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Additional registration fee required

Faculty have requested this content not be shared outside of the session

CME Credit Offered

Abstract Award

Recording available 2/16-5/2

AIUM Credit

Foundation Awardee

Poster Icons

Abstract Award

Foundation Awardee

Poster Session 3

Category: Infectious Diseases

Poster Session 3

(972) Maternal Vaccine Acceptance as a Predictor for RSV Immunization

Thursday, February 12, 2026

10:30 AM - 12:00 PM

Submitting Author and Presenting Author(s)

Stephanie Schreiber-Gonzalez, DO (she/her/hers)

Ascension Healthcare
Clarendon Hills, Illinois, United States

Coauthor(s)

Sandhya Chandrasekaran, MD, PhD (she/her/hers)

OB/GYN Resident Physician
University of Chicago
Chicago, Illinois, United States
Ashish Premkumar, MD, PhD (he/him/his)

Assistant Professor of Obstetrics and Gynecology
University of Chicago
Chicago, Illinois, United States
BP

Beth Plunkett, MD, MPH

Endeavor Health Evanston
Evanston, Illinois, United States
RR

Rachel Ruderman, MD, MPH

Endeavor Health
Chicago, Illinois, United States

Objective:
To evaluate whether acceptance of influenza, coronavirus-19 (COVID-19), and tetanus-diptheria-acellular pertussis (Tdap) vaccines are associated with acceptance of the newly-recommended respiratory syncytial virus (RSV) vaccine in pregnancy.

Study Design:
We conducted a case-control study of individuals between 32 and 36 weeks of gestation (the gestational ages at which they would be eligible for RSV vaccination) between 11/2023 and 2/2024 receiving prenatal care at two large urban and suburban medical systems. Exclusion criteria included documented allergy to prior vaccination or pregnancy affected with a lethal fetal anomaly. Covariates included vaccine acceptance defined as receipt of annual influenza and COVID-19 vaccines as well as the Tdap vaccine during pregnancy. The primary outcome was acceptance of RSV vaccination. Bivariate analyses and a logistic regression were performed to control for confounders including age, race, ethnicity, language, marital status, and insurance status. A p-value of less than 0.05 was used to determine statistical significance.

Results:
Of 1185 eligible participants, 638 (53.8%) received the RSV vaccine. On bivariate analysis, those who accepted the RSV vaccine were more likely to be older [mean age 33.0 vs 32.7 (p < 0.01)], self-identify as white [263(46.2%), p=0.01], and be married [168 (26.8%), p < 0.01](Table 1). When adjusted for confounders, acceptance of other vaccinations in pregnancy were independently associated with RSV vaccination for all three vaccines: Tdap [aOR 4.15, 95%CI (2.25-8.21)], COVID-19 [aOR 3.30, 95%CI (2.33-4.72)], and influenza [aOR 1.57, 95%CI (1.57-2.82)] (Figure 1).

Conclusion:
Maternal vaccine acceptance during pregnancy is associated with RSV vaccination, suggesting that patients with established vaccine confidence are more likely to accept new maternal immunizations. Targeted counseling for other vaccines in pregnancy may increase RSV vaccine acceptance and thus improve maternal and neonatal protection.